Akèy › Myelofibroz
Etid klinik pou Myelofibroz ap rekrite nan Etazini
55 etid pou Myelofibroz ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX19 etid
- New York City, NY18 etid
- Boston, MA12 etid
- Durham, NC12 etid
- Seattle, WA11 etid
- Columbus, OH11 etid
- Miami, FL10 etid
- Baldwin Park, CA9 etid
- Cleveland, OH9 etid
- Nashville, TN9 etid
- Tampa, FL9 etid
- Atlanta, GA9 etid
- Salt Lake City, UT9 etid
- St. Louis, MO8 etid
- Ann Arbor, MI8 etid
- Mountain View, CA7 etid
- Baltimore, MD7 etid
- Chicago, IL7 etid
- Birmingham, AL7 etid
- Winston-Salem, NC6 etid
- Philadelphia, PA6 etid
- Kansas City, MO5 etid
- Irvine, CA5 etid
- Los Angeles, CA5 etid
- Portland, OR5 etid
- Cincinnati, OH5 etid
- Dallas, TX5 etid
- Edison, NJ4 etid
- Jacksonville, FL4 etid
- Milwaukee, WI4 etid
- Denver, CO4 etid
- New Haven, CT4 etid
- Minneapolis, MN4 etid
- Charlotte, NC4 etid
- Sacramento, CA3 etid
- San Diego, CA3 etid
- Gilbert, AZ3 etid
- Aurora, CO3 etid
- Coral Springs, FL3 etid
- Charleston, SC3 etid
Pa eta
- Alabama7 etid
- Arizona7 etid
- Colorado6 etid
- Connecticut5 etid
- Florid14 etid
- Georgia9 etid
- Illinois7 etid
- Kalifòni20 etid
- Kansas6 etid
- Maryland8 etid
- Massachusetts13 etid
- Michigan10 etid
- Minnesota7 etid
- Missouri8 etid
- New Jersey6 etid
- New York21 etid
- North Carolina17 etid
- Ohio17 etid
- Oregon6 etid
- Pennsylvania8 etid
- South Carolina4 etid
- Tennessee9 etid
- Texas20 etid
- Utah9 etid
- Virginia5 etid
- Washington11 etid
- Wisconsin5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06661915A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07357727Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT04176198A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07469891A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06343805Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04282187High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 16, 2026 · NCT06345495Pacritinib Effectiveness in Real-world Settings
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07774455A Telehealth Advance Care Planning Intervention
Ap rekrite
Laj 60 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05875805A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT07623161Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 19, 2026 · NCT07228624TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Aug 17, 2026 · NCT07302776A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07008118Quantitative MRI for Myelofibrosis
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Jul 31, 2026 · NCT01973881A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07020533A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06773195Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT07250646Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jul 20, 2026 · NCT04370301Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT07128381Allo HSCT Using RIC and PTCy for Hematological Diseases
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Ap rekriteFaz 2
Jiska laj 60 · Tout sèks · Mizajou Jun 25, 2026 · NCT03314974Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.